Fresenius Medical Care AG & Co. KGaA Q2 2026 Earnings Recap

The stock dropped 7.9% following earnings as investors reacted negatively to the steeper-than-expected deceleration in U.S. same-market treatment growth, driven by operational execution issues impacting referrals and prompting a downward revision of full-year growth guidance for this key segment.

Key Takeaways

• U.S. same market treatment growth declined 0.9% in Q2, reflecting an operational miss in capturing referrals and a softening trend compared to Q1.
• Management cut 2026 U.S. same market treatment growth guidance to roughly the Q2 level due to weaker than anticipated referral trends earlier in the year.
• Despite ongoing margin improvements and EUR 67 million in sustainable cost savings from the FME25+ program, growth headwinds in the largest market overshadowed operational gains.
• International markets delivered modest 0.8% same market treatment growth, providing limited offset to U.S. weakness.
• Operational optimization efforts included exiting about 100 underperforming clinics and progress on infection reduction initiatives, but these appear insufficient to prevent investor disappointment.